Back to top
more

Agenus (AGEN)

(Real Time Quote from BATS)

$13.48 USD

13.48
427,634

+1.79 (15.31%)

Updated Apr 29, 2024 10:18 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

J&J (JNJ) Announces $5B Stock Repurchase Program, Stock Up

by Zacks Equity Research

J&J (JNJ) to buy back $5 billion worth of shares. It also reaffirms its financial guidance for 2022.

Key Factors Driving Merck's (MRK) Outperformance This Year

by Zacks Equity Research

Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.

Pfizer (PFE), BioNTech Omicron BA.4, BA.5 Boosters Get CHMP Nod

by Zacks Equity Research

Pfizer (PFE) and BioNTech (BNTX) get a positive recommendation from CHMP for Omicron BA.4 and BA.5-adapted bivalent vaccines.

Pfizer (PFE) Alopecia Drug Filings Get Accepted by FDA, EMA

by Zacks Equity Research

FDA accepts Pfizer's (PFE) NDA for ritlecitinib for treating severe alopecia areata. The EMA also accepts the MAA for a similar patient population.

Revance (RVNC) Gets FDA Nod for Anti-Wrinkle Product, Stock Up

by Zacks Equity Research

FDA approves Revance Therapeutics' (RVNC) Daxxify as a long-acting neuromodulator with a strong label that includes 36-week efficacy data from the SAKURA clinical program.

Pfizer (PFE) Streptococcus Jab Gets FDA's Breakthrough Tag

by Zacks Equity Research

Pfizer (PFE) gets Breakthrough Therapy Designation for GBS vaccine candidate, GBS6, based on an interim analysis of a phase II study.

GSK's NDA for Daprodustat to be Reviewed by an FDA Panel

by Zacks Equity Research

GSK's regulatory applications for daprodustat are based on data from the ASCEND phase III program, consisting of five studies.

AstraZeneca (AZN) Imfinzi Gets FDA Nod for Biliary Tract Cancer

by Zacks Equity Research

AstraZeneca's (AZN) Imfinzi plus chemotherapy becomes the first immunotherapy combination to get approval in the United States to treat advanced biliary tract cancer

Is Most-Watched Stock Agenus Inc. (AGEN) Worth Betting on Now?

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Agenus (AGEN). This makes it worthwhile to examine what the stock has in store.

Vertex (VRTX) CF Drug Gets FDA Expanded Label for Toddlers

by Zacks Equity Research

Following FDA approval for label expansion, Vertex Pharmaceuticals' (VRTX) Orkambi is now approved for treating cystic fibrosis in children aged one year and older.

AstraZeneca (AZN) Evusheld Gets Japan Nod as COVID Treatment

by Zacks Equity Research

AstraZeneca's (AZN) Evusheld gets approval in Japan for treating COVID-19. This is the first global approval for Evusheld as a COVID-19 treatment.

Sanofi (SNY) Hemophilia A Drug BLA Gets FDA Priority Tag

by Zacks Equity Research

Sanofi's (SNY) BLA filing for efanesoctocog alfa was based on data from the XTEND-1 pivotal phase III study.

    Vertex (VRTX) Stock Up 36% This Year So Far: What Lies Ahead?

    by Zacks Equity Research

    Vertex's (VRTX) CF sales rise 22% in the first half of 2022, primarily driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.

    Encompass Health (EHC) Up 4.7% Despite Q2 Earnings Miss

    by Zacks Equity Research

    Encompass Health (EHC) intends to open three additional de novo locations and increase the bed count by 20 in existing facilities this year.

    Community Health (CYH) Down 30.3% Since Q2 Earnings Report

    by Zacks Equity Research

    Community Health (CYH) expects capex to remain within $400-$450 million in 2022.

    Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Agenus (AGEN) delivered earnings and revenue surprises of 26.09% and 11.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

    Teladoc (TDOC) Down 10.3% Despite Q2 Earnings & Sales Beat

    by Zacks Equity Research

    Teladoc (TDOC) projects total visits between 4.8 million and 5 million for the third quarter.

    Heska (HSKA) Q2 Earnings and Revenues Miss Estimates

    by Zacks Equity Research

    Heska (HSKA) delivered earnings and revenue surprises of -8.11% and 6.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

    Centene (CNC) Q2 Earnings Beat Estimates, Boosts 2022 View

    by Zacks Equity Research

    Centene (CNC) currently has $3.4 billion remaining in its share buyback program.

    Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Agenus (AGEN) delivered earnings and revenue surprises of 34.48% and 49.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Agenus (AGEN) delivered earnings and revenue surprises of -62.50% and 46.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Do Options Traders Know Something About Agenus (AGEN) Stock We Don't?

    by Zacks Equity Research

    Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.

    Company News for Nov 10, 2021

    by Zacks Equity Research

    Companies in the news are: DHI, AGEN, IGT, NSANY

    Editas (EDIT) Q3 Earnings Beat Estimates, Revenues Fall Y/Y

    by Zacks Equity Research

    Editas (EDIT) reports narrower-than-expected loss in the third quarter of 2021 while its revenues marginally beat estimates. Focus remains on the development of lead candidate, EDIT-101.

    Apellis' (APLS) Q3 Loss Widens, Revenues Surpass Estimates

    by Zacks Equity Research

    Apellis (APLS) reports wider-than-expected loss for the third quarter of 2021 while revenues surpass expectations.